GLP-1 Medications and Mental Health, One Year Later: What the New Research Actually Shows

When we first wrote about GLP-1 medications like Ozempic, Wegovy, and Zepbound, the conversation around mental health was full of unanswered questions. Were these drugs going to help with depression? Did they raise suicide risk? Could they actually do something for addiction? A year later, we have a lot more data — and the picture is more interesting (and more honest) than the early headlines suggested.

The good news first: the FDA has walked back the suicide risk warning

One of the most persistent fears about GLP-1 medications was a possible link to suicidal thoughts or behavior. That concern made it into prescribing information and a lot of news coverage. But after a comprehensive review of the evidence, the FDA announced in January 2026 that it is requesting the removal of suicidal behavior and suicidal ideation warnings from certain GLP-1 receptor agonist medications, after finding no increased risk associated with their use. LifeStance Health

This doesn't mean mental health monitoring becomes unnecessary — anyone starting a new medication that affects appetite, weight, and metabolism should still have open conversations with their prescriber about mood. But it's a meaningful shift: one of the biggest safety question marks hanging over these drugs has largely been resolved.

The most exciting development: addiction and craving reduction

If there's one area where the research has gotten dramatically stronger over the past year, it's addiction. A large study out of Washington University School of Medicine, published in The BMJ, looked at veterans with type 2 diabetes and found that GLP-1 medication use was tied to reductions in substance use disorders and serious related outcomes across all major addictive substances studied — suggesting these drugs may target a shared biological pathway underlying addiction itself. MedicalXpress

That's a striking statement. We're not just talking about alcohol or nicotine in isolation — the effect appears to show up across substance categories, which points toward something fundamental happening in the brain's reward circuitry, not just appetite suppression.

A separate large cohort study reinforced this from a different angle: people using GLP-1 medications had notably fewer psychiatric hospital visits, lower rates of depression and anxiety diagnoses, and significantly lower rates of substance use disorders during treatment. Researchers note this could reflect a combination of lifestyle changes (better sleep, more activity, improved self-image) and direct effects of the medication on brain chemistry — but either way, for patients struggling with cravings around alcohol, nicotine, or other substances, this is becoming one of the better-supported "side benefits" of these medications. ScienceDaily

The more complicated story: depression and anxiety

Here's where we have to slow down and resist the temptation to oversell. Early enthusiasm suggested GLP-1s might work as a kind of antidepressant. The newer evidence doesn't really support that.

A 2026 systematic review pulling together the available trial data found that a large post hoc analysis of major semaglutide trials found a statistically significant but clinically negligible reduction in depressive symptoms — meaning the effect was real on paper, but too small to matter much in practice. Wiley Online Library

It gets more nuanced still. A large Swedish national registry study published in The Lancet Psychiatry specifically asked a more pointed question: for people who already have depression or anxiety, does starting a GLP-1 medication make things better or worse? The researchers noted that prior data on whether these medications alleviate or worsen anxiety, depression, and self-harm in this population has been mixed, which is exactly why this kind of focused study matters. The Lancet

The takeaway here isn't "GLP-1s are bad for mental health." It's that the relationship is individualized. Someone with well-controlled depression who starts a GLP-1 for diabetes or weight management may do fine — or even notice mood improvements tied to better physical health, sleep, and energy. But someone with an active mood disorder starting one of these medications deserves closer monitoring, not blanket assumptions in either direction.

What this means if you're considering a GLP-1

If you're weighing one of these medications — whether for diabetes, weight management, or because you've heard about the addiction-related findings — a few practical points:

• The suicide-risk concern that made headlines a couple of years ago has largely been resolved by the FDA's own review of the evidence.

  
  

• If cravings around alcohol, nicotine, or other substances are part of your picture, this is an area where the research has gotten genuinely stronger, and it's worth a conversation with your prescriber.

  
  

• Don't expect a GLP-1 to treat depression on its own. If you have an active mood or anxiety disorder, these medications aren't a substitute for psychiatric treatment — but they also aren't off the table. The key is coordination between whoever is managing your physical health and whoever is managing your mental health.

  
  

• Monitoring matters. Any time your body chemistry shifts significantly — through weight loss, appetite changes, or new medication — it's worth paying attention to mood, sleep, and energy, and reporting changes early.

  
  

As always, the research on GLP-1s and the brain is moving fast, and we'll keep following it. If you're curious how this might apply to your specific situation, that's exactly the kind of conversation worth having at your next visit with your prescriber.